Amit Hasija as Joins Fulcrum Therapeutics as Chief Business Officer

0
12
Amit Hasija

CAMBRIDGE, MA– Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, announced that Amit Hasija has joined the firm as Chief Business Officer.  The company also appointments Owen Wallace as Chief Scientific Officer.

Hasija was most recently at Sanofi where his roles included Vice President and Head of Integrated Care, leading value-based contracting for the U.S., and Vice President and Head of business development for North America.

“Fulcrum is uniquely committed to its mission of delivering a new future to patients suffering from severe genetic diseases,” said Hasija. “I’m eager to guide our strategic initiatives as we work to realize the great potential of the company’s innovative product engine and bring life- changing treatments to patients in need.”

Amit Hasija

Prior to joining Sanofi, Hasija spent more than a decade as an investment banker with Goldman Sachs, Credit Suisse and Deutsche Bank, where he executed mergers and acquisitions and corporate finance transactions for healthcare clients. He began his career at Merck in vaccine manufacturing as a planning and logistics analyst and operations manager. He earned a B.S. in chemical engineering from Drexel University and received an MBA from New York University’s Stern School of Business.

“We are pleased to be strengthening our leadership team with these key hires,” said Robert J. Gould, Ph.D., Fulcrum’s President and Chief Executive Officer. “Owen brings more than two decades of experience in drug discovery and development across multiple disease areas, including an impressive track record of delivering innovative compounds into clinical development. Amit is a respected industry leader with a wide breadth of finance, strategy and business development experience in the life sciences sector. Together, their deep expertise in their respective fields will prove invaluable to Fulcrum as we build and expand our product engine and advance our lead programs in Fragile X syndrome and facioscapulohumeral muscular dystrophy (FSHD).”

Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease.

LEAVE A REPLY

Please enter your comment!
Please enter your name here